Phaseline

Companies › KTH Biopharma

KTH Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Geniwa gel
alpha lactalbumin-oleic acid formulation
–Phase 2HPV (Human Papillomavirus)-AssociatedAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07698886Geniwa gelPhase 2HPV (Human Papillomavirus)-AssociatedInfectious diseaseAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience Frantz Viral Therapeutics Grand Theravac Life Sciences (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.